Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically recurrent prostate cancer, according to interim results from a phase III trial. In the three-arm PRESTO study, adding either apalutamide (Erleada) or apalutamide plus abiraterone acetate (Zytiga) and prednisone […]